Mar 31
SIGY · Sigyn Therapeutics, Inc.
$0.03
At close · Nov 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“The Company had an accumulated deficit of $17,379,978 at September 30, 2025, had a working capital deficit of $3,903,920 at September 30, 2025, had net losses of $578,503 and $2,698,254, and $1,196,923 and $2,817,394 for the three and nine months ended September 30, 2025 and 2024, respectively, and net cash used in operating activities of $646,208 and $582,218 for the nine months ended September 30, 2025 and 2024, respectively, with no revenue earned since inception, and a lack of operational history. These matters raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Nov 14, 2025
Market Cap
$44,951
Shares
1.61M
Volume · Nov 6
2000
Avg daily vol (3M)
22.72K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.03
Open$0.03
Day$0.03–0.03
52W close$0.02–2.00
Avg vol 30d21K
Short int2K · 0.1% of shares · 1.0d
Short vol67%
DataJan 2021–Nov 2026
Filing10-Q · Nov 14
Latest documents
2026
Feb 20
Current report
8-K
Entered into a material agreement, Unregistered sale of equity
AI summary on its way
2025
Nov 14
Quarterly report
10-Q
FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Net loss $578.5K
Diluted EPS -$0.36
Sep 5
Quarterly report
10-Q
FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Net loss $1.45M
Diluted EPS -$0.90
Aug 15
Current report
8-K
Events of Aug 14
Entered into a material agreement, Unregistered sale of equity, Director or officer change, or executive pay, Other events
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$9,929
Trailing 12 months
Net income (TTM)
−$3.22M
Trailing 12 months
Revenue growth YoY
-88.1%
Year over year
Operating margin
-361.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$3.77M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+26.5%
Year over year · more shares
Price change (1Y)
-98.6%
Trailing year
Short interest
—
Latest settlement
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.72
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−98%
below
Price vs 50-day avg
−12%
below
RSI (14)
46
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+12%
trailing
6-month return
−83%
trailing
YTD return
−98%
this year
Relative strength
−83%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 1 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.12% of shares out · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Fundamentals
Revenue growth
+406%
Y/Y
Gross margin
75%
expanding
EPS growth
+33%
Y/Y
Free cash flow
$-873.3K
Balance sheet
$2.2M
net debt
Quant / Vol
risk profile
Volatility
369%
annualized · 1-yr
Max drawdown
−100%
past year
ATR
26.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−98%
Bearish
Price vs 50-day avg
−12%
Bearish
RSI (14)
46
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 1 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.12% of shares out · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $2
vs 200-day avg -98%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SIGY
this stock
Sigyn Therapeutics, Inc.
|
$44,951 | -98.4% | +405.6% | — | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$137.57B | +19.7% | +46.2% | 34.9 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.40B | +23.2% | +20.8% | 21.0 | 2.1% |
|
MRNA
Moderna, Inc.
|
$93.61B | +684.5% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.55B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Holders
1
- % held
- 3.3%
- Reported
- 1 of 1
- Top holder
- Howard Capital Management…
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SIGY | -6.7% | +12.0% | -83.1% | +0.0% | -98.4% |
| SPY | -2.7% | -5.6% | -0.5% | -2.7% | +7.8% |
| vs SPY | -4.0% | +17.6% | -82.7% | +2.7% | -106.2% |